NASDAQ:CFMS - ConforMIS Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.29 -0.01 (-0.77 %)
(As of 05/24/2018 01:31 PM ET)
Previous Close$1.29
Today's Range$1.29 - $1.30
52-Week Range$1.15 - $5.73
Volume8,001 shs
Average Volume516,451 shs
Market Capitalization$79.79 million
P/E Ratio-1.04
Dividend YieldN/A
Beta1.02

About ConforMIS (NASDAQ:CFMS)

ConforMIS logoConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001

Debt

Debt-to-Equity Ratio0.49
Current Ratio5.95
Quick Ratio5.34

Price-To-Earnings

Trailing P/E Ratio-1.04
Forward P/E Ratio-1.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$78.11 million
Price / Sales1.01
Cash FlowN/A
Price / CashN/A
Book Value$0.99 per share
Price / Book1.30

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-53,580,000.00
Net Margins-62.63%
Return on Equity-83.49%
Return on Assets-46.31%

Miscellaneous

Employees350
Outstanding Shares60,910,000

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How were ConforMIS's earnings last quarter?

ConforMIS (NASDAQ:CFMS) announced its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. The medical instruments supplier had revenue of $19.66 million for the quarter, compared to analysts' expectations of $19.51 million. ConforMIS had a negative return on equity of 83.49% and a negative net margin of 62.63%. View ConforMIS's Earnings History.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for ConforMIS.

What price target have analysts set for CFMS?

6 equities research analysts have issued 12 month price targets for ConforMIS's shares. Their forecasts range from $3.00 to $5.00. On average, they expect ConforMIS's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:
  • 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (4/18/2018)
  • 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with ConforMIS management as well as visit the company’s booth at AAOS. Overall, we came away incrementally positive on the opportunities ahead of ConforMIS and continue to think commercial momentum through the H1/18 could represent an inflection point in the business. Specifically, we think the commercial changes implemented mid-2017, including new leadership, sales rep hiring, and the build-out of a corporate accounts team position the company with the opportunity for increased productivity into the H2/18. From our recent meetings with management, we highlight additional clinical data that bolsters the company’s implant technology and a strong product pipeline that should support market momentum over the next several years." (3/12/2018)

Who are some of ConforMIS's key competitors?

Who are ConforMIS's key executives?

ConforMIS's management team includes the folowing people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 52)
  • Dr. Philipp Lang M.D., MBA, Founder & Director (Age 55)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 54)
  • Dr. Daniel Steines M.D., MS, Chief Technology Officer (Age 49)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 52)

When did ConforMIS IPO?

(CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Has ConforMIS been receiving favorable news coverage?

Media stories about CFMS stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ConforMIS earned a media sentiment score of 0.15 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 46.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are ConforMIS's major shareholders?

ConforMIS's stock is owned by many different of retail and institutional investors. Top institutional investors include Archon Capital Management LLC (4.99%), BlackRock Inc. (3.94%), Sio Capital Management LLC (3.61%), Platinum Investment Management Ltd. (0.98%), Northern Trust Corp (0.88%) and Millennium Management LLC (0.68%). Company insiders that own ConforMIS stock include Bradley Langdale, Daniel Steines, David Cerveny, Kenneth P Fallon III, Mark A Augusti, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.

Which institutional investors are selling ConforMIS stock?

CFMS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold ConforMIS company stock in the last year include Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Paul S Weiner and Philipp Lang. View Insider Buying and Selling for ConforMIS.

Which institutional investors are buying ConforMIS stock?

CFMS stock was bought by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, Sio Capital Management LLC, Platinum Investment Management Ltd., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Northern Trust Corp, Schwab Charles Investment Management Inc. and BlackRock Inc.. View Insider Buying and Selling for ConforMIS.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $1.29.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $79.79 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]


MarketBeat Community Rating for ConforMIS (CFMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ConforMIS (NASDAQ:CFMS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for ConforMIS in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 210.08%. The high price target for CFMS is $5.00 and the low price target for CFMS is $3.00. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.572.432.40
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.75$4.75$6.1250
Price Target Upside: 210.08% upside249.26% upside241.73% upside73.02% upside

ConforMIS (NASDAQ:CFMS) Consensus Price Target History

Price Target History for ConforMIS (NASDAQ:CFMS)

ConforMIS (NASDAQ:CFMS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018OppenheimerSet Price TargetBuy$4.00LowView Rating Details
5/3/2018BTIG ResearchReiterated RatingBuy$3.00LowView Rating Details
4/10/2018Canaccord GenuityUpgradeHold ➝ Buy$4.00HighView Rating Details
2/21/2018CowenInitiated CoverageOutperform$1.39 ➝ $4.00HighView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMediumView Rating Details
8/4/2017Deutsche BankReiterated RatingBuy ➝ Hold$6.00 ➝ $5.00HighView Rating Details
5/16/2017B. RileyReiterated RatingBuy$7.50LowView Rating Details
9/19/2016SunTrust BanksInitiated CoverageBuy$14.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

ConforMIS (NASDAQ:CFMS) Earnings History and Estimates Chart

Earnings by Quarter for ConforMIS (NASDAQ:CFMS)

ConforMIS (NASDAQ:CFMS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.04)
2019 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.34)($0.24)($0.28)
Q2 20183($0.34)($0.21)($0.26)
Q3 20183($0.34)($0.21)($0.25)
Q4 20183($0.34)($0.17)($0.24)
Q1 20191($0.17)($0.17)($0.17)
Q2 20191($0.16)($0.16)($0.16)
Q3 20191($0.16)($0.16)($0.16)
Q4 20191($0.15)($0.15)($0.15)

ConforMIS (NASDAQ CFMS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.21)N/AView Earnings Details
5/2/2018Q1 2018($0.25)($0.22)$19.51 million$19.66 millionViewListenView Earnings Details
2/7/2018Q4 2017($0.30)($0.27)$20.07 million$20.80 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.32)($0.29)$17.55 million$18.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.36)($0.28)$19.34 million$18.50 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.36)($0.40)$18.48 million$20.50 millionViewN/AView Earnings Details
2/15/2017Q416($0.30)($0.37)$21.37 million$21.70 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.31)$18.27 million$18.60 millionViewListenView Earnings Details
8/8/2016Q216($0.35)($0.34)$18.02 million$19.30 millionViewListenView Earnings Details
5/12/2016Q116($0.38)($0.37)$19.23 million$20.30 millionViewListenView Earnings Details
2/11/2016Q415($0.41)($0.37)$17.23 million$19.10 millionViewListenView Earnings Details
11/2/2015Q3($0.38)($0.45)$13.51 million$13.90 millionViewN/AView Earnings Details
8/11/2015Q215($1.31)($2.51)$11.20 million$19.20 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ConforMIS (NASDAQ:CFMS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ConforMIS (NASDAQ CFMS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.59%
Institutional Ownership Percentage: 44.04%
Insider Trading History for ConforMIS (NASDAQ:CFMS)
Institutional Ownership by Quarter for ConforMIS (NASDAQ:CFMS)

ConforMIS (NASDAQ CFMS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Daniel SteinesInsiderSell3,480$1.30$4,524.00241,281View SEC Filing  
5/16/2018Mark A AugustiCEOSell7,638$1.30$9,929.40592,805View SEC Filing  
5/16/2018Paul S WeinerCFOSell3,711$1.30$4,824.30319,290View SEC Filing  
5/2/2018Bradley LangdaleDirectorSell9,465$1.35$12,777.7521,304View SEC Filing  
4/30/2018Daniel SteinesInsiderSell277,064$1.41$390,660.24232,307View SEC Filing  
4/30/2018Philipp LangDirectorSell651,212$1.38$898,672.5695,055View SEC Filing  
4/26/2018Bradley LangdaleDirectorSell75,764$1.52$115,161.2895,055View SEC Filing  
4/26/2018Daniel SteinesCTOSell13,900$1.51$20,989.00232,307View SEC Filing  
2/6/2018Daniel SteinesInsiderSell3,632$1.30$4,721.60142,963View SEC Filing  
2/6/2018Paul S WeinerCFOSell2,674$1.30$3,476.20157,009View SEC Filing  
2/6/2018Philipp LangDirectorSell3,737$1.30$4,858.10590,375View SEC Filing  
12/19/2017David CervenyInsiderSell5,478$2.27$12,435.06152,073View SEC Filing  
12/19/2017Mark A AugustiCEOSell16,548$2.27$37,563.96285,007View SEC Filing  
12/19/2017Paul S WeinerCFOSell7,433$2.27$16,872.91167,116View SEC Filing  
12/5/2017Mark A AugustiCEOSell4,189$2.68$11,226.52236,163View SEC Filing  
11/15/2017Daniel SteinesCTOSell15,485$3.15$48,777.75254,652View SEC Filing  
11/15/2017David CervenyInsiderSell16,392$3.17$51,962.64151,408View SEC Filing  
11/15/2017Paul S WeinerCFOSell17,723$3.17$56,181.91162,009View SEC Filing  
10/18/2017Daniel SteinesCTOSell907$3.51$3,183.57254,652View SEC Filing  
10/18/2017Philipp LangDirectorSell1,839$3.53$6,491.67594,112View SEC Filing  
6/20/2017Bradley LangdaleDirectorSell6,722$4.30$28,904.6026,533View SEC Filing  
4/26/2017Daniel SteinesInsiderSell5,000$5.54$27,700.00190,745View SEC Filing  
4/5/2017Daniel SteinesInsiderSell5,000$5.00$25,000.00195,745View SEC Filing  
2/15/2017Philipp LangDirectorSell137,968$8.60$1,186,524.80558,759View SEC Filing  
2/3/2017David CervenyInsiderSell3,569$8.59$30,657.7187,501View SEC Filing  
2/3/2017Paul S WeinerCFOSell2,676$8.42$22,531.9282,115View SEC Filing  
2/3/2017Philipp LangDirectorSell108,705$8.60$934,863.00519,411View SEC Filing  
1/25/2017Philipp LangDirectorSell108,985$8.60$937,271.00558,153View SEC Filing  
1/23/2017Philipp LangDirectorSell9,681$8.60$83,256.60519,784View SEC Filing  
1/13/2017Philipp LangDirectorSell37,275$8.60$320,565.00514,769View SEC Filing  
1/11/2017Philipp LangDirectorSell2,800$8.62$24,136.00516,019View SEC Filing  
1/10/2017Philipp LangDirectorSell83,909$8.64$724,973.76516,119View SEC Filing  
1/9/2017Philipp LangDirectorSell6,200$8.65$53,630.00516,119View SEC Filing  
1/5/2017Philipp LangDirectorSell400$8.60$3,440.00514,719View SEC Filing  
1/3/2017Philipp LangDirectorSell74,876$8.00$599,008.00589,495View SEC Filing  
12/30/2016Philipp LangDirectorSell168,734$8.25$1,392,055.50547,639View SEC Filing  
12/28/2016Philipp LangDirectorSell58,547$8.26$483,598.22532,981View SEC Filing  
12/27/2016Philipp LangDirectorSell42,086$8.57$360,677.02520,939View SEC Filing  
12/23/2016Philipp LangDirectorSell30,647$8.62$264,177.14520,939View SEC Filing  
10/17/2016Daniel SteinesInsiderSell889$8.64$7,680.96214,324View SEC Filing  
10/17/2016Paul S WeinerCFOSell884$8.60$7,602.4084,791View SEC Filing  
10/12/2016Daniel SteinesInsiderSell10,000$9.66$96,600.00215,213View SEC Filing  
10/5/2016Philipp LangCEOSell53,860$10.19$548,833.40483,378View SEC Filing  
10/4/2016Philipp LangCEOSell400$10.00$4,000.00483,378View SEC Filing  
10/3/2016Daniel SteinesCTOSell10,000$10.03$100,300.00225,213View SEC Filing  
10/3/2016Philipp LangCEOSell10,410$10.03$104,412.30483,378View SEC Filing  
9/16/2016Daniel SteinesInsiderSell30,000$9.09$272,700.00245,213View SEC Filing  
8/17/2016Kenneth P Fallon IIIDirectorSell4,000$8.44$33,760.0092,222View SEC Filing  
5/17/2016Robert Law IIISVPBuy1,600$6.20$9,920.0024,793View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ConforMIS (NASDAQ CFMS) News Headlines

Source:
DateHeadline
ConforMIS (CFMS) Given Consensus Recommendation of "Hold" by BrokeragesConforMIS (CFMS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 24 at 11:55 AM
Analyzing Wright Medical Group (WMGI) and ConforMIS (CFMS)Analyzing Wright Medical Group (WMGI) and ConforMIS (CFMS)
www.americanbankingnews.com - May 23 at 9:18 PM
New Research: Key Drivers of Growth for PCM, WGL, Savara, ConforMIS, Sandy Spring, and West Pharmaceutical ...New Research: Key Drivers of Growth for PCM, WGL, Savara, ConforMIS, Sandy Spring, and West Pharmaceutical ...
globenewswire.com - May 23 at 5:51 PM
Reviewing ConforMIS (CFMS) & Lakeland Industries (LAKE)Reviewing ConforMIS (CFMS) & Lakeland Industries (LAKE)
www.americanbankingnews.com - May 22 at 7:04 PM
 Brokerages Expect ConforMIS (CFMS) Will Post Quarterly Sales of $19.48 Million Brokerages Expect ConforMIS (CFMS) Will Post Quarterly Sales of $19.48 Million
www.americanbankingnews.com - May 16 at 2:53 AM
Zacks: Brokerages Anticipate ConforMIS (CFMS) Will Announce Earnings of -$0.21 Per ShareZacks: Brokerages Anticipate ConforMIS (CFMS) Will Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - May 14 at 1:20 PM
Form 4 ConforMIS Inc For: May 07 Filed by: Steines DanielForm 4 ConforMIS Inc For: May 07 Filed by: Steines Daniel
www.streetinsider.com - May 10 at 8:06 AM
Analysts Set Expectations for ConforMISs Q3 2018 Earnings (CFMS)Analysts Set Expectations for ConforMIS's Q3 2018 Earnings (CFMS)
www.americanbankingnews.com - May 7 at 3:24 AM
BTIG Research Reiterates Buy Rating for ConforMIS (CFMS)BTIG Research Reiterates Buy Rating for ConforMIS (CFMS)
www.americanbankingnews.com - May 3 at 11:51 PM
ConforMIS (CFMS) Upgraded at ValuEngineConforMIS (CFMS) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM
Bradley Langdale Sells 9,465 Shares of ConforMIS (CFMS) StockBradley Langdale Sells 9,465 Shares of ConforMIS (CFMS) Stock
www.americanbankingnews.com - May 3 at 8:45 PM
ConforMIS (CFMS) Issues  Earnings ResultsConforMIS (CFMS) Issues Earnings Results
www.americanbankingnews.com - May 3 at 3:34 PM
ConforMIS (CFMS) PT Set at $4.00 by OppenheimerConforMIS (CFMS) PT Set at $4.00 by Oppenheimer
www.americanbankingnews.com - May 3 at 12:52 PM
ConforMIS (CFMS) CEO Mark Augusti on Q1 2018 Results - Earnings Call TranscriptConforMIS' (CFMS) CEO Mark Augusti on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:06 AM
Edited Transcript of CFMS earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of CFMS earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:06 AM
ConforMIS: 1Q Earnings SnapshotConforMIS: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:06 AM
Are ConforMIS Inc’s (NASDAQ:CFMS) Interest Costs Too High?Are ConforMIS Inc’s (NASDAQ:CFMS) Interest Costs Too High?
finance.yahoo.com - May 2 at 5:45 PM
Conformis Reports First Quarter 2018 Financial ResultsConformis Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 5:45 PM
ConforMIS (CFMS) to Release Earnings on TuesdayConforMIS (CFMS) to Release Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:08 AM
Insider Selling: ConforMIS (CFMS) Director Sells 651,212 Shares of StockInsider Selling: ConforMIS (CFMS) Director Sells 651,212 Shares of Stock
www.americanbankingnews.com - April 30 at 10:10 PM
ConforMIS (CFMS) Insider Daniel Steines Sells 277,064 SharesConforMIS (CFMS) Insider Daniel Steines Sells 277,064 Shares
www.americanbankingnews.com - April 30 at 10:10 PM
ConforMIS (CFMS) Director Sells $115,161.28 in StockConforMIS (CFMS) Director Sells $115,161.28 in Stock
www.americanbankingnews.com - April 30 at 10:10 PM
Insider Selling: ConforMIS (CFMS) CTO Sells 13,900 Shares of StockInsider Selling: ConforMIS (CFMS) CTO Sells 13,900 Shares of Stock
www.americanbankingnews.com - April 30 at 10:10 PM
ConforMIS (CFMS) Receives Average Recommendation of "Hold" from AnalystsConforMIS (CFMS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 8:24 AM
 Brokerages Expect ConforMIS (CFMS) Will Announce Quarterly Sales of $19.51 Million Brokerages Expect ConforMIS (CFMS) Will Announce Quarterly Sales of $19.51 Million
www.americanbankingnews.com - April 29 at 5:50 AM
-$0.26 Earnings Per Share Expected for ConforMIS (CFMS) This Quarter-$0.26 Earnings Per Share Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 27 at 1:29 AM
ConforMISs (CFMS) "Hold" Rating Reiterated at BTIG ResearchConforMIS's (CFMS) "Hold" Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 20 at 2:25 PM
ConforMIS (CFMS) Downgraded to Sell at Zacks Investment ResearchConforMIS (CFMS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:10 PM
Conformis to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 2, 2018Conformis to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 2, 2018
finance.yahoo.com - April 12 at 5:51 PM
$19.51 Million in Sales Expected for ConforMIS (CFMS) This Quarter$19.51 Million in Sales Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 12 at 5:19 AM
Benzingas Top Upgrades, Downgrades For April 10, 2018Benzinga's Top Upgrades, Downgrades For April 10, 2018
www.benzinga.com - April 10 at 5:46 PM
UPDATE: Canaccord Genuity Upgrades ConforMIS (CFMS) to BuyUPDATE: Canaccord Genuity Upgrades ConforMIS (CFMS) to Buy
www.streetinsider.com - April 10 at 5:46 PM
ConforMIS (CFMS) Rating Increased to Buy at Canaccord GenuityConforMIS (CFMS) Rating Increased to Buy at Canaccord Genuity
www.americanbankingnews.com - April 10 at 8:29 AM
-$0.26 EPS Expected for ConforMIS (CFMS) This Quarter-$0.26 EPS Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 10 at 3:13 AM
ConforMIS Inc (CFMS) Given Average Rating of "Hold" by BrokeragesConforMIS Inc (CFMS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 9:58 AM
ConforMIS (CFMS) Cut to Hold at Zacks Investment ResearchConforMIS (CFMS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:45 PM
ConforMIS (CFMS) Rating Lowered to Strong Sell at ValuEngineConforMIS (CFMS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
ConforMIS (CFMS) Stock Rating Upgraded by Zacks Investment ResearchConforMIS (CFMS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM
ConforMIS (CFMS) Given Hold Rating at BTIG ResearchConforMIS (CFMS) Given Hold Rating at BTIG Research
www.americanbankingnews.com - April 2 at 8:39 AM
JPMorgan Chase Downgrades ConforMIS (CFMS) to UnderweightJPMorgan Chase Downgrades ConforMIS (CFMS) to Underweight
www.americanbankingnews.com - March 31 at 11:54 AM
Market Trends Toward New Normal in ConforMIS, Equity Commonwealth, SendGrid, Granite Point Mortgage Trust, Stewart Information Services, and South State — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in ConforMIS, Equity Commonwealth, SendGrid, Granite Point Mortgage Trust, Stewart Information Services, and South State — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - March 30 at 8:03 AM
ConforMIS Inc (CFMS) Expected to Post Quarterly Sales of $19.51 MillionConforMIS Inc (CFMS) Expected to Post Quarterly Sales of $19.51 Million
www.americanbankingnews.com - March 26 at 7:53 AM
ConforMIS (CFMS) Earns "Buy" Rating from OppenheimerConforMIS (CFMS) Earns "Buy" Rating from Oppenheimer
www.americanbankingnews.com - March 22 at 4:09 PM
ConforMIS (CFMS) Upgraded to "Buy" by Zacks Investment ResearchConforMIS (CFMS) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
ConforMISs (CFMS) "Hold" Rating Reiterated at Canaccord GenuityConforMIS's (CFMS) "Hold" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - March 12 at 9:22 PM
Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Baxter, ConforMIS, DENTSPLY SIRONA, and ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Baxter, ConforMIS, DENTSPLY SIRONA, and ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 6:58 AM
ConforMIS Inc (CFMS) Given Consensus Rating of "Hold" by AnalystsConforMIS Inc (CFMS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 7:36 AM
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the ... - GlobeNewswire (press release)Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:20 AM
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CRFour-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
finance.yahoo.com - March 7 at 8:20 AM
Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in ... - GlobeNewswire (press release)Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:24 AM

SEC Filings

ConforMIS (NASDAQ:CFMS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ConforMIS (NASDAQ:CFMS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ConforMIS (NASDAQ CFMS) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.